Jasleen Kaur, Karim Arroub, Alexander Drzezga, Klaus Schomäcker and Sanjay Mathur
Org. Biomol. Chem., 2021,19, 9849-9854
DOI:
10.1039/D1OB01812D,
Communication
In this work, we describe the synthesis, in vitro stability, and preliminary biological evaluation of [177Lu]Lu–DOTA–p160 peptide-based radiopharmaceuticals. Our findings highlight that all DOTA–p160–peptide radioconjugates exhibit favorable proteolytic and enzymatic stability with a prolonged half-life in human plasma and serum. Cell uptake studies carried out on MCF-7 cell line revealed saturable binding of the radioconjugates in the nanomolar range, thereby demonstrating their promising potential in the imaging and therapy of breast tumors.